文献速递核素与放射性配体治疗

长效放射性标记生长抑素类似物177Lu-DOTA-EB-TATE在晚期转移性神经内分泌肿瘤患者中的安全性、药代动力学和剂量学研究

Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors.
PubMed 文献 · J Nucl Med · 2018-04-13

本首次人体研究纳入8例晚期转移性神经内分泌肿瘤患者,5例接受单次0.35-0.70 GBq的177Lu-DOTA-EB-TATE并系列显像,3例接受0.28-0.41 GBq的177Lu-DOTATATE对照显像。结果显示177Lu-DOTA-EB-TATE耐受良好,肿瘤剂量递送较177Lu-DOTATATE提高7.9倍,但肾脏和骨髓剂量分别增加3.2倍和18.2倍。

要点

  • 177Lu-DOTA-EB-TATE给药耐受良好,所有患者未报告不良症状。
  • 与177Lu-DOTATATE相比,177Lu-DOTA-EB-TATE肿瘤剂量递送提高7.9倍。
  • 177Lu-DOTA-EB-TATE的肾脏和骨髓剂量分别增加3.2倍和18.2倍。

核心结论

  • 通过引入白蛋白结合基团,177Lu-DOTA-EB-TATE在神经内分泌肿瘤中显示出显著更高的摄取和滞留,同时肾脏和红骨髓的蓄积也显著增加。
  • 177Lu-DOTA-EB-TATE有潜力以更低剂量和更少给药频率用于神经内分泌肿瘤的肽受体放射性核素治疗。

研究设计与样本

  • 首次人体研究,纳入8例(6男2女,年龄范围27-61岁)晚期转移性神经内分泌肿瘤患者。
  • 5例患者接受单次0.35-0.70 GBq(9.5-18.9 mCi)的177Lu-DOTA-EB-TATE,并在注射后2、24、72、120和168小时进行系列全身平面和SPECT/CT扫描。
  • 另3例患者接受静脉注射0.28-0.41 GBq(7.5-11.1 mCi)的177Lu-DOTATATE,并在注射后1、3、4、24和72小时进行相同的显像采集程序。
  • 剂量学使用OLINDA/EXM 1.1软件计算。

主要发现

  • 177Lu-DOTA-EB-TATE给药耐受良好,所有患者未注意到或报告不良症状。
  • 与177Lu-DOTATATE相比,177Lu-DOTA-EB-TATE在血液中循环时间延长,肿瘤剂量递送提高7.9倍。
  • 全身有效剂量:177Lu-DOTA-EB-TATE组为0.205 ± 0.161 mSv/MBq,177Lu-DOTATATE组为0.174 ± 0.072 mSv/MBq。
  • 与接受177Lu-DOTATATE的患者相比,接受177Lu-DOTA-EB-TATE的患者肾脏和骨髓剂量递送分别增加3.2倍和18.2倍。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radiolabeled somatostatin analog therapy has become an established treatment method for patients with well to moderately differentiated unresectable or metastatic neuroendocrine tumors (NETs). The most frequently used somatostatin analogs in clinical practice are octreotide and octreotate. However, both peptides showed suboptimal retention within tumors. The aim of this first-in-humans study is to explore the safety and dosimetry of a long-acting radiolabeled somatostatin analog, 177Lu-1, 4, 7, 10-tetra-azacyclododecane-1, 4, 7, 10-tetraacetic acid-Evans blue-octreotate (177Lu-DOTA-EB-TATE). Methods: Eight patients (6 men and 2 women; age range, 27-61 y) with advanced metastatic NETs were recruited. Five patients received a single dose, 0.35-0.70 GBq (9.5-18.9 mCi), of 177Lu-DOTA-EB-TATE and underwent serial whole-body planar and SPECT/CT scans at 2, 24, 72, 120, and 168 h after injection. The other 3 patients received intravenous injection of 0.28-0.41 GBq (7.5-11.1 mCi) of 177Lu-DOTATATE for the same imaging acquisition procedures at 1, 3, 4, 24, and 72 h after injection. The dosimetry was calculated using the OLINDA/EXM 1.1 software. Results: Administration of 177Lu-DOTA-EB-TATE was well tolerated, with no adverse symptoms being noticed or reported in any of the patients. Compared with 177Lu-DOTATATE, 177Lu-DOTA-EB-TATE showed extended circulation in the blood and achieved a 7.9-fold increase of tumor dose delivery. The total-body effective doses were 0.205 ± 0.161 mSv/MBq for 177Lu-DOTA-EB-TATE and 0.174 ± 0.072 mSv/MBq for 177Lu-DOTATATE. Significant dose delivery increases to the kidneys and bone marrow were also observed in patients receiving 177Lu-DOTA-EB-TATE compared with those receiving 177Lu-DOTATATE (3.2 and 18.2-fold, respectively). Conclusion: By introducing an albumin-binding moiety, 177Lu-DOTA-EB-TATE showed remarkably higher uptake and retention in NETs as well as significantly increased accumulation in the kidneys and red marrow. It has great potential to be used in peptide receptor radionuclide therapy for NETs with lower dose and less frequency of administration.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zhang J, Wang H, Jacobson O, et al. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors. J Nucl Med. 2018. PMID: 29653971. doi:10.2967/jnumed.118.209841

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。